SCHEMBL4146334

SCHEMBL4146334

Cc1c(S(C)(=O)=O)cc(C(C)(C)C)c(O)c1C(=O)Nc1ccc(C#N)cc1OC(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.38
GCGR P47871 1/20 0.38
PTGFR P43088 1/20 0.35
PDK1 Q15118 2/20 0.35
PDK2 Q15119 2/20 0.35
PDK3 Q15120 2/20 0.35
PDK4 Q16654 2/20 0.35
PGR P06401 1/20 0.34
TBXA2R P21731 5/20 0.33
TMPRSS4 Q9NRS4 1/20 0.33
IDH1 O75874 1/20 0.33
SLC22A12 Q96S37 2/20 0.32
BACE2 Q9Y5Z0 1/20 0.32
XDH P47989 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CYP3A4 P08684 1/20 0.32
CACNA1C Q13936 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138666 0.90 GCGR (0.39) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4150028 0.88 GCGR (0.39) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4149540 0.88 GCGR (0.39) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4136944 0.87 PDK1 (0.42) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL3170148 0.87 PTGFR (0.39) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4146506 0.87 GCGR (0.39) GCGRPTGFRPDK1PDK2PDK3
SCHEMBL4146555 0.87 PGR (0.45) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4148816 0.86 GCGR (0.38) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4140219 0.86 GCGR (0.38) CNR2GCGRPTGFRPDK1PDK2
SCHEMBL4133940 0.86 GCGR (0.36) CNR2GCGRPTGFRPDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US claimed
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides NOVO NORDISK A/S (DK) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062396-A1 Novel Haloalkoxy-Substituted Salicylic Anilides FABP4, HDHD5, HSPD1 CNR2 169/4885GCGR 1042/4885PTGFR 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.